NVO Novo Nordisk A/S
NVO Novo Nordisk A/S
Healthcare · Drug Manufacturers - General
Market read
Scan convergence 1 scan as of 2026-08-14 1 neutral converging
POC $46.53 · VWAP $46.86 · -4.2% vs 12m avg buyer
Insiders no data — outside the Form 4 poll — US-filer feed only (foreign filers report via MAR managers'-transactions notices)
Coverage
1 related perspective
NVO Price Structure
Loading timeframes…
Peers
Every watchlist NVO belongs to, members best 30-day change first — NVO highlighted in place. Each pill: 30d change, 1d/7d, and a close spark over the last 30 calendar days (~21 sessions); hover for price, RSI, and the full chart.
@peptide-economy
@biotech-scan
Reported EPS $6.18 versus analyst consensus of $4.98 (+24.0%).
full note →Against street estimates
How NVO's reported EPS compared with analyst consensus. Street estimates are single-source vendor consensus (yfinance). Actuals are vendor consensus-basis EPS (often non-GAAP); edgarEps is GAAP diluted from filings — disputed flags large disagreement only. EPS only.
News (last pull)
Headlines about NVO from the desk's news pull — links go to the publisher. Not a desk read: the market read above is the desk's own.
pulled 35 days ago · Jul 14
- Novo Nordisk’s denecimig (Mim8) demonstrated positive results in long term safety and efficacy in phase 3 hemophilia A FRONTIER extension study at ISTH 2026
- Novo Nordisk to showcase new data across its haemophilia portfolio at the ISTH Congress 2026, featuring investigational denecimig
- Novo Nordisk’s CagriSema 2.4 mg / 2.4 mg demonstrated significant reduction in HbA1c and weight across multiple studies in the REIMAGINE program presented at ADA 2026
- NVO Rallies 11% in a Month: How Should Investors Play the Stock?
- Novo Nordisk (NVO) is Attracting Investor Attention: Here is What You Should Know
NVO research tape
34 dated scans, research, and events, newest first — the full record. Desk commentary and scheduled prints sit in their own panes.